Literature DB >> 34473380

Zoledronate alters natural progression of tissue-engineered vascular grafts.

Yu-Chun Chang1,2, Junlang Li1, Gabriel Mirhaidari1,2, Jacob Zbinden1,3, Jenny Barker1,4, Kevin Blum1,3, James Reinhardt1, Cameron Best1,2, John Kelly1, Toshihiro Shoji1, Tai Yi1, Christopher Breuer1.   

Abstract

Macrophages are a critical driver of neovessel formation in tissue-engineered vascular grafts (TEVGs), but also contribute to graft stenosis, a leading clinical trial complication. Macrophage depletion via liposomal delivery of clodronate, a first-generation bisphosphonate, mitigates stenosis, but simultaneously leads to a complete lack of tissue development in TEVGs. This result and the associated difficulty of utilizing liposomal delivery means that clodronate may not be an ideal means of preventing graft stenosis. Newer generation bisphosphonates, such as zoledronate, may have differential effects on graft development with more facile drug delivery. We sought to examine the effect of zoledronate on TEVG neotissue formation and its potential application for mitigating TEVG stenosis. Thus, mice implanted with TEVGs received zoledronate or no treatment and were monitored by serial ultrasound for graft dilation and stenosis. After two weeks, TEVGs were explanted for histological examination. The overall graft area and remaining graft material (polyglycolic-acid) were higher in the zoledronate treatment group. These effects were associated with a corresponding decrease in macrophage infiltration. In addition, zoledronate affected the deposition of collagen in TEVGs, specifically, total and mature collagen. These differences may be, in part, explained by a depletion of leukocytes within the bone marrow that subsequently led to a decrease in the number of tissue-infiltrating macrophages. TEVGs from zoledronate-treated mice demonstrated a significantly greater degree of smooth muscle cell presence. There was no statistical difference in graft patency between treatment and control groups. While zoledronate led to a decrease in the number of macrophages in the TEVGs, the severity of stenosis appears to have increased significantly. Zoledronate treatment demonstrates that the process of smooth muscle cell-mediated neointimal hyperplasia may occur separately from a macrophage-mediated mechanism.
© 2021 Federation of American Societies for Experimental Biology.

Entities:  

Keywords:  bisphosphonates; inflammation; macrophages; neovessel; stenosis

Mesh:

Substances:

Year:  2021        PMID: 34473380      PMCID: PMC8647171          DOI: 10.1096/fj.202001606RR

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.834


  42 in total

1.  Macrophages as potential targets for zoledronic acid outside the skeleton-evidence from in vitro and in vivo models.

Authors:  T L Rogers; N Wind; R Hughes; F Nutter; H K Brown; I Vasiliadou; P D Ottewell; I Holen
Journal:  Cell Oncol (Dordr)       Date:  2013-11-01       Impact factor: 6.730

2.  Tissue-engineered Vascular Grafts in Children With Congenital Heart Disease: Intermediate Term Follow-up.

Authors:  Tadahisa Sugiura; Goki Matsumura; Shinka Miyamoto; Hideki Miyachi; Christopher K Breuer; Toshiharu Shinoka
Journal:  Semin Thorac Cardiovasc Surg       Date:  2018-02-07

Review 3.  Macrophages in Tissue Repair, Regeneration, and Fibrosis.

Authors:  Thomas A Wynn; Kevin M Vannella
Journal:  Immunity       Date:  2016-03-15       Impact factor: 31.745

4.  Differential outcomes of venous and arterial tissue engineered vascular grafts highlight the importance of coupling long-term implantation studies with computational modeling.

Authors:  Cameron A Best; Jason M Szafron; Kevin A Rocco; Jacob Zbinden; Ethan W Dean; Mark W Maxfield; Hirotsugu Kurobe; Shuhei Tara; Paul S Bagi; Brooks V Udelsman; Ramak Khosravi; Tai Yi; Toshiharu Shinoka; Jay D Humphrey; Christopher K Breuer
Journal:  Acta Biomater       Date:  2019-06-12       Impact factor: 8.947

5.  A critical role for macrophages in neovessel formation and the development of stenosis in tissue-engineered vascular grafts.

Authors:  Narutoshi Hibino; Tai Yi; Daniel R Duncan; Animesh Rathore; Ethan Dean; Yuji Naito; Alan Dardik; Themis Kyriakides; Joseph Madri; Jordan S Pober; Toshiharu Shinoka; Christopher K Breuer
Journal:  FASEB J       Date:  2011-08-24       Impact factor: 5.191

6.  Differences between bisphosphonates in binding affinities for hydroxyapatite.

Authors:  M A Lawson; Z Xia; B L Barnett; J T Triffitt; R J Phipps; J E Dunford; R M Locklin; F H Ebetino; R G G Russell
Journal:  J Biomed Mater Res B Appl Biomater       Date:  2010-01       Impact factor: 3.368

7.  Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model.

Authors:  Jason D Roh; Gregory N Nelson; Matthew P Brennan; Tamar L Mirensky; Tai Yi; Tyrone F Hazlett; George Tellides; Albert J Sinusas; Jordan S Pober; W M Saltzman; Themis R Kyriakides; Christopher K Breuer
Journal:  Biomaterials       Date:  2007-12-27       Impact factor: 12.479

8.  Clodronate-Liposome Mediated Macrophage Depletion Abrogates Multiple Myeloma Tumor Establishment In Vivo.

Authors:  Khatora S Opperman; Kate Vandyke; Kimberley C Clark; Elizabeth A Coulter; Duncan R Hewett; Krzysztof M Mrozik; Nisha Schwarz; Andreas Evdokiou; Peter I Croucher; Peter J Psaltis; Jacqueline E Noll; Andrew Cw Zannettino
Journal:  Neoplasia       Date:  2019-06-24       Impact factor: 5.715

Review 9.  Advances and Challenges of Liposome Assisted Drug Delivery.

Authors:  Lisa Sercombe; Tejaswi Veerati; Fatemeh Moheimani; Sherry Y Wu; Anil K Sood; Susan Hua
Journal:  Front Pharmacol       Date:  2015-12-01       Impact factor: 5.810

10.  Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells.

Authors:  Raffaella Sabatino; Antonella Antonelli; Serafina Battistelli; Reto Schwendener; Mauro Magnani; Luigia Rossi
Journal:  PLoS One       Date:  2014-06-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.